Clinical Trial Update: BAY3401016; Biomarker Study Alport [Phase 2]

View source ↗

Summary

A Phase 2 biomarker study of BAY3401016 for Alport syndrome is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alport Syndrome

Drugs mentioned

• BAY3401016

Snippet

Sponsor: Bayer | Conditions: Alport Syndrome | Phase 2 | Status: RECRUITING